Wyniki wyszukiwania:

The development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatment of breast cancer, such as trastuzamab (Herceptin, targeting HER-2 positive tumors) and lapatinib (Tykerb, targeting tumors with mutated/overexpressed EGFR 1 and 2). Other agents specifically targeting the estrogen receptor, the aromatose pathway and microtubule dynamics, fulvestrant (Faslodex, targeting...

This issue, focusing on Breast Cancer, includes topics such as: Radiation Therapy for DCIS, Axillary dissection, Pathology in the age of personalized breast cancer treatment:, Clinical implications for breast cancer subsets defined by molecular diagnostics, Management of CNS Metastases in Breast Cancer, Endocrine therapy for advanced breast cancer, Targeting the PI3K pathway in breast cancer, Treating the Older Breast Cancer Patient, Adjuvant chemotherapy in the age of targeted treatment, and Novel radiotherapy approaches for early breast cancer